Start Mountain Region

West Valley City, Utah 84119

37 studies enrolling now · 63 studies all time

What they study most

ALK-Positive Lung Cancer, ALK-positive NSCLC, ALK-positive Non-small Cell Lung Cancer, Adenoid Cystic Carcinoma, Advanced Breast Cancer, Advanced Cancer, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Malignancies, Advanced Ovarian Carcinoma, Advanced Solid Malignancies, Advanced Solid Tumor

Studies at this site

• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer — Recruiting now
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer — Recruiting now
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors — Recruiting now
• Study of Oral MRT-2359 With Apalutamide in Prostate Cancer — Recruiting now
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) — Recruiting now
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors — Recruiting now
• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC — Recruiting now
• A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors — Recruiting now
• A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors — Recruiting now
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors — Recruiting now
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors — Recruiting now
• Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors — Recruiting now
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors — Recruiting now
• A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors — Recruiting now
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors — Recruiting now
• A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors — Recruiting now
• A Study of LY4175408 in Participants With Advanced Cancer — Recruiting now
• A Study of LY4170156 in Participants With Selected Advanced Solid Tumors — Recruiting now
• A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors — Recruiting now
• Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors — Recruiting now
• A Phase 1/1b Study of IAM1363 in HER2 Cancers — Recruiting now
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies — Recruiting now
• A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer — Recruiting now
• Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors — Recruiting now
• Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies — Recruiting now
• Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors — Recruiting now
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors — Recruiting now
• A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors — Recruiting now
• PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer — Recruiting now
• Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors — Recruiting now
• Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors — Recruiting now
• A Study of MGC026 in Participants With Advanced Solid Tumors — Recruiting now
• A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors — Recruiting now
• Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment — Recruiting now
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors — Recruiting now
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies — Stopped early
• A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors — Stopped early
• A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors — Running, not enrolling
• A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors — Stopped early
• A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer — Running, not enrolling
• A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 — Enrolling by invitation
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) — Running, not enrolling
• A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors — Running, not enrolling
• A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer — Completed
• Study of LP-184 in Patients With Advanced Solid Tumors — Running, not enrolling
• A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. — Running, not enrolling
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. — Stopped early
• Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination — Running, not enrolling